Mark, P. B. , Papworth, R., Ramparsad, N., Tomlinson, L. A., Sahwney, S., Black, C., McConnachie, A. and McCowan, C. (2020) Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors. British Journal of Clinical Pharmacology, 86(1), pp. 121-131. (doi: 10.1111/bcp.14141) (PMID:31663151)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
197804.pdf - Accepted Version 486kB |
Abstract
Aims: Therapy with angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is a mainstay of treatment for heart failure (HF), diabetes mellitus (DM) and chronic kidney disease (CKD). These agents have been associated with development of acute kidney injury (AKI) during intercurrent illness. Risk factors for AKI in patients prescribed ACEi/ARB therapy are not well described. Methods: We captured the incidence of AKI in patients commencing ACEi/ARB during 2009–2015 using anonymised patient records. Hospital‐coded AKI was defined from hospital episode statistics; biochemical AKI was ascertained from laboratory data. Risk factors for biochemically detected and hospitalised AKI were investigated. Results: Of 61,318 patients prescribed ACEi/ARB, with 132 885 person years (py) follow‐up, there were 1070 hospitalisations with AKI as a diagnosis recorded and a total of 4645 AKI events, including AKI episodes indicated by biochemical KDIGO‐based creatinine change criteria. Incidence of any AKI event was 35.0 per 1000‐py, hospital‐coded AKI was 7.8 per 1000‐py and biochemical AKI was 33.7 per 1000‐py. Independent risk factors in a multivariable model for hospital‐coded AKI events were age, male gender, HF, diabetes, cerebrovascular disease, lower estimated glomerular filtration rate, socioeconomic deprivation, diuretic or non‐steroidal anti‐inflammatory use (all P < 0.001). Conclusion: In patients prescribed ACEi/ARB, the highest risk of AKI is associated with conditions which are considered strong evidence‐based indications for their prescription. Socio‐economic status is an under‐reported risk factor for AKI with these agents. Strategies targeted at prevention of AKI may be of benefit, such as enhanced awareness based on higher risk comorbidities.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | McConnachie, Professor Alex and Mark, Professor Patrick and Ramparsad, Mr Nitish and Mccowan, Professor Colin and Papworth, Dr Richard |
| Authors: | Mark, P. B., Papworth, R., Ramparsad, N., Tomlinson, L. A., Sahwney, S., Black, C., McConnachie, A., and McCowan, C. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
| Journal Name: | British Journal of Clinical Pharmacology |
| Publisher: | Wiley |
| ISSN: | 0306-5251 |
| ISSN (Online): | 1365-2125 |
| Published Online: | 29 October 2019 |
| Copyright Holders: | Copyright © 2019 The British Pharmacological Society |
| First Published: | First published in Neurosignals 86(1):121-131 |
| Publisher Policy: | Reproduced in accordance with the copyright policy of the publisher |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information